Client of a consultant lobbyist
Dr. Reddy's Laboratories
- Meetings this Parliament
- 6
- With MPs
- 0
- Since Nov 2021
- 6
- Active registrations
- 1
Most recent reported meeting: Jun 5, 2026.
Lobbying by Dr. Reddy's Laboratories: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Apr 20, 2026
Consultant Carys Baker of Sussex Strategy Group
Consultant lobbyists
- Carys Baker
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC)
What they're lobbying on (1)Hide details
- Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
Registration 945238-381694-2. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Carys Baker · Consultant
- Daniel MacDonald · Director General, Health Canada (HC)
- Samir Khan · Director, Health Canada (HC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
-
Reported by Carys Baker · Consultant
- Neeraj Bhalla · Director of Community Outreach, Global Affairs Canada (GAC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
-
Reported by Carys Baker · Consultant
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sven Schirmer · Senior Advisor, Health Canada (HC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
-
Reported by Carys Baker · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
-
Reported by Carys Baker · Consultant
- Kelly Robinson · Director General, Health Canada (HC)
- Stephanie Parra · Associate Director, Health Canada (HC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
-
Reported by Carys Baker · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.